Acrivon Therapeutics, Inc.

As of May 3, 2024, the trend has shifted to mildly bullish due to positive weekly MACD and RSI signals, but caution is advised due to bearish daily moving averages and mixed signals from Bollinger Bands and KST.

Acrivon Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $20 million and a market cap of $37.94 million. Key metrics include a P/E ratio of NA, a dividend yield of 0.00%, and a return on equity of -52.22%.

As of Jun 18, Acrivon Therapeutics, Inc. has a market capitalization of 37.94 million, with net sales of 0.00 million and a net profit of -83.75 million over the last four quarters. The company reported shareholder's funds of 176.79 million and total assets of 196.59 million as of Dec 24.